| XENON PHARMACEUTICALS |
| Kanada |
| Gesundheit |
| CA98420N1050 / A12ETN |
| XP0 (Frankfurt) / XENE (NASDAQ) |
| FRA:XP0, ETR:XP0, XP0:GR, NASDAQ:XENE |
| - |
| https://www.xenon-pharma... |
|
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company that develops therapies for neurological and psychiatric disorders. Xenon Pharmaceuticals Inc. concentrates on ion channel science and small-molecule drug discovery, with ..
>Volltext.. |
| 3351.61 Mio. EUR |
| 2542.91 Mio. EUR |
| - |
| -382.39 Mio. EUR |
| -356.28 Mio. EUR |
| -4.13 EUR |
| 5.59 Mio. EUR |
| 104.07 Mio. EUR |
| -291.71 Mio. EUR |
| 20.68 |
| -100% |
| -51.7% |
| - |
| - |
| - |
| XENON PHARMACEUTICALS, XENON PHARMACEUTICAL, XENON PHARMA |
| 19.09.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|